John Newman
Stock Analyst at Canaccord Genuity
(2.04)
# 3,037
Out of 4,981 analysts
79
Total ratings
42.65%
Success rate
-7.09%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $850 | $560.00 | +51.79% | 17 | Jul 23, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.13 | +1,138.94% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $96.74 | +77.22% | 8 | Mar 11, 2025 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 | $12.12 | +40.26% | 5 | Mar 11, 2025 | |
| MRKR Marker Therapeutics | Initiates: Buy | $8 | $0.95 | +738.05% | 1 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Maintains: Buy | $20 → $25 | $4.79 | +421.92% | 2 | Feb 26, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $200 | $15.91 | +1,157.07% | 9 | Nov 14, 2024 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $10.84 | +93.73% | 1 | Oct 18, 2024 | |
| ACLX Arcellx | Maintains: Buy | $85 → $115 | $76.19 | +50.94% | 8 | Oct 17, 2024 | |
| ACET Adicet Bio | Maintains: Buy | $19 → $8 | $0.81 | +887.41% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 | $69.53 | -3.64% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $9.68 | +344.21% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.28 | +290.63% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $36.77 | +19.66% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $17.93 | +111.94% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $5.39 | +400.93% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $12.75 | - | 1 | Sep 13, 2017 |
Regeneron Pharmaceuticals
Jul 23, 2025
Maintains: Buy
Price Target: $850
Current: $560.00
Upside: +51.79%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.13
Upside: +1,138.94%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $96.74
Upside: +77.22%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $12.12
Upside: +40.26%
Marker Therapeutics
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $0.95
Upside: +738.05%
Candel Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $4.79
Upside: +421.92%
Seres Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $200
Current: $15.91
Upside: +1,157.07%
Delcath Systems
Oct 18, 2024
Maintains: Buy
Price Target: $21
Current: $10.84
Upside: +93.73%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85 → $115
Current: $76.19
Upside: +50.94%
Adicet Bio
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.81
Upside: +887.41%
Jul 25, 2024
Maintains: Buy
Price Target: $67
Current: $69.53
Upside: -3.64%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $9.68
Upside: +344.21%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $1.28
Upside: +290.63%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $36.77
Upside: +19.66%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $17.93
Upside: +111.94%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $5.39
Upside: +400.93%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $12.75
Upside: -